Source:http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/346
| Subject | Predicate | Object | Context |
|---|---|---|---|
| dailymed-drugs:346 | rdf:type | http://www4.wiwiss.fu-berli... | lld:dailymed |
| dailymed-drugs:346 | rdf:type | dailymed-instance:drugs | lld:dailymed |
| dailymed-drugs:346 | rdfs:label | DiaBeta (Tablet) | lld:dailymed |
| dailymed-drugs:346 | dailymed-instance:dosage | There is no fixed dosage regimen for the management of diabetes mellitus with Dia��eta or any other hypoglycemic agent. The patient's fasting blood glucose must be measured periodically to determine the minimum effective dose for the patient; to detect primary failure, i.e., inadequate lowering of blood glucose at the maximum recommended dose of medication; and to detect secondary failure, i.e., loss of adequate blood glucose lowering response after an initial period of effectiveness. Periodic glycosylated hemoglobin determinations should be performed. Short-term administration of Dia��eta may be sufficient during periods of transient loss of control in patients usually controlled well on diet. In elderly patients, debilitated or malnourished patients, and patients with impaired renal or hepatic function, the initial and maintenance dosing should be conservative to avoid hypoglycemic reactions. | lld:dailymed |
| dailymed-drugs:346 | dailymed-instance:descripti... | Dia��eta (glyburide USP) is an oral blood-glucose-lowering drug of the sulfonylurea class. It is a white, crystalline compound, formulated as tablets of 1.25 mg, 2.5 mg, and 5 mg strengths for oral administration. Dia��eta tablets contain the active ingredient glyburide and the following inactive ingredients: dibasic calcium phosphate USP, magnesium stearate NF, microcrystalline cellulose NF, sodium alginate NF, talc USP. Dia��eta 1.25 mg tablets also contain D&C Yellow #10 Aluminum Lake and FD&C Red #40 Aluminum Lake. Dia��eta 2.5 mg tablets also contain FD&C Red #40 Aluminum Lake. Dia��eta 5 mg tablets also contain D&C Yellow #10 Aluminum Lake, and FD&C Blue #1. Chemically, Dia��eta is identified as 1-[[p-[2-(5-Chloro-o-anisamido)ethyl]phenyl]sulfonyl]-3-cyclohexylurea. The CAS Registry Number is 10238-21-8. The structural formula is: The molecular weight is 493.99. The aqueous solubility of Dia��eta increases with pH as a result of salt formation. | lld:dailymed |
| dailymed-drugs:346 | dailymed-instance:clinicalP... | Dia��eta appears to lower the blood glucose acutely by stimulating the release of insulin from the pancreas, an effect dependent upon functioning beta cells in the pancreatic islets. The mechanism by which Dia��eta lowers blood glucose during long-term administration has not been clearly established. With chronic administration in Type II diabetic patients, the blood glucose lowering effect persists despite a gradual decline in the insulin secretory response to the drug. Extrapancreatic effects may play a part in the mechanism of action of oral sulfonylurea hypoglycemic drugs. In addition to its blood glucose lowering actions, Dia��eta produces a mild diuresis by enhancement of renal free water clearance. Clinical experience to date indicates an extremely low incidence of disulfiram-like reactions in patients while taking Dia��eta.<br/>Pharmacokinetics: Single-dose studies with Dia��eta in normal subjects demonstrate significant absorption within one hour, peak drug levels at about four hours, and low but detectable levels at twenty-four hours. Mean serum levels of glyburide, as reflected by areas under the serum concentration-time curve, increase in proportion to corresponding increases in dose. Multiple-dose studies with Dia��eta in diabetic patients demonstrate drug level concentration-time curves similar to single-dose studies, indicating no build-up of drug in tissue depots. The decrease of glyburide in the serum of normal healthy individuals is biphasic, the terminal half-life being about 10 hours. In single-dose studies in fasting normal subjects, the degree and duration of blood glucose lowering is proportional to the dose administered and to the area under the drug level concentration-time curve. The blood glucose lowering effect persists for 24 hours following single morning doses in non-fasting diabetic patients. Under conditions of repeated administration in diabetic patients, however, there is no reliable correlation between blood drug levels and fasting blood glucose levels. A one-year study of diabetic patients treated with Dia��eta showed no reliable correlation between administered dose and serum drug level. The major metabolite of Dia��eta is the 4-trans-hydroxy derivative. A second metabolite, the 3-cis-hydroxy derivative, also occurs. These metabolites contribute no significant hypoglycemic action since they are only weakly active (1/400th and 1/40th, respectively, as glyburide) in rabbits. Dia��eta is excreted as metabolites in the bile and urine, approximately 50% by each route. This dual excretory pathway is qualitatively different from that of other sulfonylureas, which are excreted primarily in the urine. Sulfonylurea drugs are extensively bound to serum proteins. Displacement from protein binding sites by other drugs may lead to enhanced hypoglycemic action. In vitro, the protein binding exhibited by Dia��eta is predominantly non-ionic, whereas that of other sulfonylureas (chlorpropamide, tolbutamide, tolazamide) is predominantly ionic. Acidic drugs such as phenylbutazone, warfarin, and salicylates displace the ionic-binding sulfonylureas from serum proteins to a far greater extent than the non-ionic binding Dia��eta. It has not been shown that this difference in protein binding will result in fewer drug-drug interactions with Dia��eta in clinical use. | lld:dailymed |
| dailymed-drugs:346 | dailymed-instance:activeIng... | dailymed-ingredient:glyburi... | lld:dailymed |
| dailymed-drugs:346 | dailymed-instance:contraind... | Dia��eta is contraindicated in patients with: | lld:dailymed |
| dailymed-drugs:346 | dailymed-instance:supply | Dia��eta (glyburide USP) tablets are available in the following strengths and package sizes: 1.25 mg (peach, capsule-shaped, flat faced, beveled edge tablet debossed "Dia��" with a score line between the "Dia" and the "��" on one side and plain on the other side). Bottles of 50 (NDC 0039-0053-05) 2.5 mg (pink, capsule-shaped, flat faced, beveled edge tablet debossed "Dia��" with a score line between the "Dia" and "��" on one side and plain on the other side). Bottles of 100 (NDC 0039-0051-10) Bottles of 500 (NDC 0039-0051-50) 5 mg (green, capsule-shaped, flat faced, beveled edge tablet debossed "Dia��" with a score line between the "Dia" and "��" on one side and plain on the other side). Bottles of 100 (NDC 0039-0052-10) Bottles of 500 (NDC 0039-0052-50) Bottles of 1000 (NDC 0039-0052-70) Store at 25��C (77��F); excursions permitted to 15���30��C (59���86��F) [See USP Controlled Room Temperature]. Dispense in well-closed containers with safety closures. | lld:dailymed |
| dailymed-drugs:346 | dailymed-instance:activeMoi... | dailymed-ingredient:glyburi... | lld:dailymed |
| dailymed-drugs:346 | dailymed-instance:inactiveI... | dailymed-ingredient:magnesi... | lld:dailymed |
| dailymed-drugs:346 | dailymed-instance:inactiveI... | dailymed-ingredient:microcr... | lld:dailymed |
| dailymed-drugs:346 | dailymed-instance:inactiveI... | dailymed-ingredient:talc | lld:dailymed |
| dailymed-drugs:346 | dailymed-instance:inactiveI... | dailymed-ingredient:sodium_... | lld:dailymed |
| dailymed-drugs:346 | dailymed-instance:inactiveI... | dailymed-ingredient:dibasic... | lld:dailymed |
| dailymed-drugs:346 | dailymed-instance:inactiveI... | dailymed-ingredient:D&C_Yel... | lld:dailymed |
| dailymed-drugs:346 | dailymed-instance:inactiveI... | dailymed-ingredient:FD&C_Re... | lld:dailymed |
| dailymed-drugs:346 | dailymed-instance:genericMe... | glyburide | lld:dailymed |
| dailymed-drugs:346 | dailymed-instance:fullName | DiaBeta (Tablet) | lld:dailymed |
| dailymed-drugs:346 | dailymed-instance:adverseRe... | Hypoglycemia: See PRECAUTIONS and OVERDOSAGE Sections. Gastrointestinal Reactions: Cholestatic jaundice and hepatitis may occur rarely; Dia��eta should be discontinued if this occurs. Liver function abnormalities, including isolated transaminase elevations, have been reported. Gastrointestinal disturbances, e.g., nausea, epigastric fullness, and heartburn, are the most common reactions and occur in 1.8% of treated patients. They tend to be dose-related and may disappear when dosage is reduced. Dermatologic Reactions: Allergic skin reactions, e.g., pruritus, erythema, urticaria, and morbilliform or maculopapular eruptions, occur in 1.5% of treated patients. These may be transient and may disappear despite continued use of Dia��eta; if skin reactions persist, the drug should be discontinued. Porphyria cutanea tarda and photosensitivity reactions have been reported with sulfonylureas. Hematologic Reactions: Leukopenia, agranulocytosis, thrombocytopenia, which occasionally may present as purpura, hemolytic anemia, aplastic anemia, and pancytopenia have been reported with sulfonylureas. Metabolic Reactions: Hepatic porphyria reactions have been reported with sulfonylureas; however, these have not been reported with Dia��eta. Disulfiram-like reactions have been reported very rarely with Dia��eta. Cases of hyponatremia have been reported with glyburide and all other sulfonylureas, most often in patients who are on other medications or have medical conditions known to cause hyponatremia or increase release of antidiuretic hormone. The syndrome of inappropriate antidiuretic hormone (SIADH) secretion has been reported with certain other sulfonylureas, and it has been suggested that these sulfonylureas may augment the peripheral (antidiuretic) action of ADH and/or increase release of ADH. Other Reactions: Changes in accommodation and/or blurred vision have been reported with glyburide and other sulfonylureas. These are thought to be related to fluctuation in glucose levels. In addition to dermatologic reactions, allergic reactions such as angioedema, arthralgia, myalgia and vasculitis have been reported. | lld:dailymed |
| dailymed-drugs:346 | dailymed-instance:warning | SPECIAL WARNING ON INCREASED RISK OF CARDIOVASCULAR MORTALITY: The administration of oral hypoglycemic drugs has been reported to be associated with increased cardiovascular mortality as compared to treatment with diet alone or diet plus insulin. This warning is based on the study conducted by the University Group Diabetes Program (UGDP), a long-term prospective clinical trial designed to evaluate the effectiveness of glucose-lowering drugs in preventing or delaying vascular complications in patients with non-insulin-dependent diabetes. The study involved 823 patients who were randomly assigned to one of four treatment groups (Diabetes 19 (supp. 2): 747���830, 1970). UGDP reported that patients treated for 5 to 8 years with diet plus a fixed dose of tolbutamide (1.5 grams per day) had a rate of cardiovascular mortality approximately 2-1/2 times that of patients treated with diet alone. A significant increase in total mortality was not observed, but the use of tolbutamide was discontinued based on the increase in cardiovascular mortality, thus limiting the opportunity for the study to show an increase in overall mortality. Despite controversy regarding the interpretation of these results, the findings of the UGDP study provide an adequate basis for this warning. The patient should be informed of the potential risks and advantages of Dia��eta and of alternative modes of therapy. Although only one drug in the sulfonylurea class (tolbutamide) was included in this study, it is prudent from a safety standpoint to consider that this warning may also apply to other oral hypoglycemic drugs in this class, in view of their close similarities in mode of action and chemical structure. | lld:dailymed |
| dailymed-drugs:346 | dailymed-instance:indicatio... | Dia��eta is indicated as an adjunct to diet to lower the blood glucose in patients with non-insulin-dependent diabetes mellitus (Type II) whose hyperglycemia cannot be controlled by diet alone. In initiating treatment for non-insulin-dependent diabetes, diet should be emphasized as the primary form of treatment. Caloric restriction and weight loss are essential in the obese diabetic patient. Proper dietary management alone may be effective in controlling the blood glucose and symptoms of hyperglycemia. The importance of regular physical activity should also be stressed, and cardiovascular risk factors should be identified and corrective measures taken where possible. If this treatment program fails to reduce symptoms and/or blood glucose, the use of an oral sulfonylurea or insulin should be considered. Use of Dia��eta must be viewed by both the physician and patient as a treatment in addition to diet, and not as a substitute for diet or as a convenient mechanism for avoiding dietary restraint. Furthermore, loss of blood glucose control on diet alone may be transient, thus requiring only short-term administration of Dia��eta. During maintenance programs, Dia��eta should be discontinued if satisfactory lowering of blood glucose is no longer achieved. Judgments should be based on regular clinical and laboratory evaluations. In considering the use of Dia��eta in asymptomatic patients, it should be recognized that controlling the blood glucose in non-insulin dependent diabetes has not been definitely established to be effective in preventing the long-term cardiovascular or neural complications of diabetes. | lld:dailymed |
| dailymed-drugs:346 | dailymed-instance:represent... | http://www4.wiwiss.fu-berli... | lld:dailymed |
| dailymed-drugs:346 | dailymed-instance:routeOfAd... | http://www4.wiwiss.fu-berli... | lld:dailymed |
| dailymed-drugs:346 | dailymed-instance:name | DiaBeta | lld:dailymed |
| http://www4.wiwiss.fu-berli... | dailymed-instance:producesD... | dailymed-drugs:346 | lld:dailymed |